Megan Blewett is an Associate at Venrock, a venture capital firm
based in Palo Alto, California. Megan focuses on investments in early-stage
therapeutics companies. She also works with Venrock teammates to build
companies from the ground up.
Megan has a long-standing interest in developing new therapies for
autoimmune conditions, and for her PhD determined at a molecular level how the
widely prescribed multiple sclerosis drug Tecfidera blocks immune cell
activation. This work revealed new, potentially much safer, therapeutic
approaches for suppressing the immune system and formed the foundation for the
biotechnology company Vividion. Vividion has since raised over $50M in venture
Megan’s PhD work, under Benjamin Cravatt at The Scripps Research
Institute, was supported by the National Science Foundation Graduate Research
Fellowship and the Hertz Foundation Fellowship. The Hertz Fellowship is awarded
to only 10-15 PhD students each year, across all the sciences, and is the most
competitive and prestigious graduate fellowship in science and engineering.
Also while a PhD student, Megan founded the healthcare analytics
company VoxHealth. Google partnered with VoxHealth to expand its health
Knowledge Graph, and VoxHealth data is now viewed by millions of people every
day in Google’s medical condition search results – alongside data from
institutions such as Mayo Clinic and Harvard Medical School. Megan currently
serves as a consultant to Google’s health condition search team.
Megan received her AB from Harvard, where she worked in the lab of
Nobel prizewinner E.J. Corey and was co-author on three separate publications. For
this work, she was awarded the Thomas T. Hoopes Prize for “outstanding
scholarly work or research” in a senior thesis.
2018 - The Newman Entrepreneurial Initiative
Indicator, co-founded with John Cannon, Justin Norden, and Hertz Fellows Ashvin Bashyam and Aman Sinha